Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.

MLA

Horáková, Dana, et al. “Proportion of Alemtuzumab-Treated Patients Converting from Relapsing-Remitting Multiple Sclerosis to Secondary Progressive Multiple Sclerosis over 6 Years.” Multiple Sclerosis Journal - Experimental, Translational & Clinical, Dec. 2020, pp. 1–10. EBSCOhost, https://doi.org/10.1177/2055217320972137.

APA

Horáková, D., Boster, A., Bertolotto, A., Freedman, M. S., Firmino, , Isabel, Cavalier, S. J., Jacobs, , Alan K, Thangavelu, , Karthinathan, Daizadeh, N., Poole, , Elizabeth M, Baker, D. P., Margolin, , David H, & Ziemssen, T. (2020). Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. Multiple Sclerosis Journal - Experimental, Translational & Clinical, 1–10. https://doi.org/10.1177/2055217320972137

Chicago

Horáková, Dana, Aaron Boster, Antonio Bertolotto, Mark S Freedman, , Isabel Firmino, Steven J Cavalier, , Alan K Jacobs, et al. 2020. “Proportion of Alemtuzumab-Treated Patients Converting from Relapsing-Remitting Multiple Sclerosis to Secondary Progressive Multiple Sclerosis over 6 Years.” Multiple Sclerosis Journal - Experimental, Translational & Clinical, December, 1–10. doi:10.1177/2055217320972137.